Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Anders Berggren, MD, PhD
AstraZeneca
Study Director - Matthew Heeney, MD
Harvard Medical School (HMS and HSDM)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
55 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Brussels, Belgium
- Research Site
Edegem, Belgium
- Research Site
Porto Alegre, Brazil
- Research Site
Rio de Janeiro, Brazil
- Research Site
Salvador, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
Al Sharkeya, Egypt
- Research Site
Alexandria, Egypt
- Research Site
Cairo, Egypt
- Research Site
Cairo, Egypt
- Research Site
Cairo, Egypt
- Research Site
Dakahlia, Egypt
- Research Site
Accra, Ghana
- Research Site
Ho, Ghana
- Research Site
Kumasi, Ghana
- Research Site
Athens, Greece
- Research Site
Mumbai, India
- Research Site
Nagpur, India
- Research Site
Nagpur, India
- Research Site
Pune, India
- Research Site
Pune, India
- Research Site
Wardha, India
- Research Site
Catania, Italy
- Research Site
Naples, Italy
- Research Site
Padova, Italy
- Research Site
Verona, Italy
- Research Site
Kisumu, Kenya
- Research Site
Nairobi, Kenya
- Research Site
Siaya, Kenya
- Research Site
Beirut, Lebanon
- Research Site
Tripoli, Lebanon
- Research Site
Cape Town, South Africa
- Research Site
Soweto, South Africa
- Research Site
Barakaldo, Spain
- Research Site
Barcelona, Spain
- Research Site
Madrid, Spain
- Research Site
Madrid, Spain
- Research Site
Mbeya, Tanzania
- Research Site
Antalya, Turkey (Türkiye)
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Sept 2018
- Primary completion
- 13 Aug 2020
- Completion
- 13 Aug 2020
- Last update posted
- 9 Apr 2021
- Registered enrollment
- 193
- Registry id
- NCT03615924
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.